Your search for osteoporosis returned 308 results

Findings show a protective effect against osteopenia in both current and past users.

Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types.

In subgroup analyses, lower risk was seen with cumulative dosage of 401mg or greater, or with therapy duration of 5 years or longer.

The BLA is supported by a comprehensive data package that includes data from the phase 1/3 ROSALIA study.

Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.

Bisphosphonates strongly recommended for initial treatment of primary osteoporosis for postmenopausal women

Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo.

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.

Researchers conducted a 6-year longitudinal cohort study that analyzed the impact of glucocorticoid intake at varying doses

Sequential treatment emphasized, with additional therapy needed after discontinuation of initial drug